# Sermorelin Dosage in the Research: Doses Studied, Half-Life, and Routes

> Sermorelin dosage as documented in the research: the doses and routes studied (subcutaneous, IV, intranasal), the short half-life, and why injection beats tablets — no human dosing advice.

What was given, to whom, by which route, in the published studies — reported as research context, never as a recommendation.

## Read this first

This page reports the sermorelin dosage that researchers used in published studies. It is not a how-to and it is not advice. We describe what was given, to which group, by which route — never a dose for you to take. Two plain facts shape everything here. First, sermorelin leaves the bloodstream fast: it has a very short half-life (the time for half a dose to clear), on the order of 10-12 minutes after an intravenous dose [4]. Even so, one dose keeps growth hormone (GH) raised for about 3 hours. Second, the body absorbs it well by injection under the skin but very poorly any other way — only about 3-5% gets in through the nose [4]. That is why the studied route is almost always a subcutaneous injection, and why tablets and drops are doubted. The numbers below are study context, full stop.

## Sermorelin dosage

The sermorelin dosage figures in the literature span very different research goals, so they are not comparable to one another and none is a personal recommendation. In the pediatric growth-deficiency efficacy work, the studied amount was 30 mcg/kg/day given subcutaneously at bedtime. In aging research, older men received 0.5 mg and 1 mg subcutaneously twice daily for 14 days, which produced dose-related rises in GH and IGF-1 [3]. In pharmacokinetic testing, intravenous doses of 0.25-2 mcg/kg were enough to trigger GH release in healthy men, with the response maxing out around 1-2 mcg/kg [4]. Historically, a single intravenous bolus (commonly about 1 mcg/kg) was also used as a diagnostic test of the pituitary's GH reserve. These are documented research doses, reported here as context only.

## Half-life and timing

Sermorelin's defining quirk is how quickly it comes and goes. After an intravenous dose, roughly half clears in about 10-12 minutes [4], yet that brief signal is enough to lift GH for around 3 hours. Researchers find this short, sharp action a feature, not a bug: it produces a *pulse* of GH rather than a flat, continuous level, which is closer to the body's own pattern [6]. Bedtime administration appears repeatedly in the study designs because the body's largest natural GH pulse comes during deep sleep, so a nighttime signal layers onto that natural rhythm. The native peptide's short life is also the reason chemists engineered longer-acting GHRH analogs — for example, adding a D-Ala2 substitution or albumin-binding 'DAC' technology to stretch the effect.

## Sermorelin injection

The sermorelin injection — given subcutaneously, into the fat just under the skin — is the route nearly every human study used, because it is where GHRH(1-29) actually gets absorbed [3][4]. In research settings, lyophilized (freeze-dried) sermorelin acetate powder is reconstituted with sterile diluent and then kept refrigerated, because peptides dissolved in water break down over time. Compounded preparations are made under USP <797> sterile-compounding standards. None of this is an instruction to self-inject; it is a description of how the studied material was handled and delivered.

## Sermorelin tablets

Sermorelin tablets, capsules, sublingual troches, and oral drops are common in the consumer marketplace, but the pharmacology works against them. Peptides like sermorelin are digested and broken apart in the gut, and they cross the lining of the mouth poorly — which is why research-user communities are openly skeptical that oral or sublingual forms match injection. The supporting data point is the nasal study: even by a mucous membrane, only about 3-5% of a GHRH(1-29) dose was absorbed [4]. There is no controlled trial showing an oral sermorelin tablet reliably raises GH the way the injected, studied route does.

## Sermorelin injection vs other routes

Across the literature, three routes appear. Subcutaneous injection is the primary studied route and the one tied to the GH/IGF-1 results [3]. Intravenous dosing shows up in diagnostic and pharmacokinetic work, where GHRH(1-29) raised GH at doses as low as 0.25 mcg/kg [4]. Intranasal delivery was tested historically but reached only 3-5% bioavailability [4]. The takeaway, drawn straight from the studies: route matters enormously for a peptide this fragile, and the evidence base sits almost entirely on injection.

---

A plain-English reading room that traces the GHRH(1-29) signal from pituitary to IGF-1 — every figure wired back to its study, the fat-loss data tagged as tesamorelin where it belongs, and the missing long-term adult evidence left openly unlit; no clinic behind the console and nothing here dosed, compounded, or sold.